Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO 2019

European Society for Medical Oncology Congress
Barcelona, 27th September – 1st October

The European Society for Medical Oncology (ESMO) 2019 Congress, in Barcelona, Spain, took place from the 27 September – 1 October, during which the European Oncology Nursing Society (EONS) 12 conference also took place. VJOncology was there to cover the latest data straight from the experts, including trial updates, late-breaking abstracts, and press briefings.

Genitourinary Cancer

View all
2:33
irAEs with single-agent PD-1 vs PD-L1 inhibitors
Petros Grivas • 30 Sep 2019
9:59
PROfound performance: olaparib vs. enzalutamide or abiraterone for HRR altered mCRPC
Maha Hussain

Breast Cancer

View all
4:18
IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC
David Spigel
4:20
KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC
Peter Schmid

Lung Cancer

View all
2:33
CheckMate 227: chemo-free NSCLC treatment
Solange Peters • 30 Sep 2019
1:49
SCLC hyperprogression with nivolumab
Martin Reck • 29 Sep 2019

Gastrointestinal Cancer

View all
3:58
Atezolizumab and bevacizumab for upfront unresectable HCC
Michael Lee • 28 Sep 2019
2:14
FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma
Arndt Vogel • 29 Sep 2019

Skin Cancer

View all
0:53
POLARIS: encorafenib/binimetinib for advanced BRAFV600+ melanoma
Georgina Long • 28 Sep 2019
3:24
Who are the long-term responders to immuno and targeted therapy in melanoma?
Paolo Ascierto • 28 Sep 2019

Gynecological Cancer

View all
4:34
Niraparib in newly diagnosed advanced ovarian cancer: PRIMA results
Antonio González Martín • 29 Sep 2019
5:03
FORWARD I: mirvetuximab soravtansine vs chemo in platinum-resistant ovarian cancer
Kathleen Moore • 29 Sep 2019
The content of VJOncology is intended for healthcare professionals